Friday, 24 November 2017
Latest news
Main » Gilead Sciences, Inc. (GILD) Downgraded by Argus to Hold

Gilead Sciences, Inc. (GILD) Downgraded by Argus to Hold

15 November 2017

About 50 shares traded. About shares traded. Novocure Ltd (NASDAQ:NVCR) has declined 0.43% since November 14, 2016 and is downtrending. It has underperformed by 17.22% the S&P500.

Healthcare Trust of America, Inc.is a real estate investment trust. (MA) by 8.57% based on its latest 2017Q2 regulatory filing with the SEC. (NASDAQ:GILD) was sold by Alton Gregg H. The institutional investor held 80,000 shares of the business services company at the end of 2017Q2, valued at $9.72 million, down from 87,500 at the end of the previous reported quarter. The 5 months chart pattern indicates low risk for the $1.52 billion company. The stock decreased 1.25% or $0.92 during the last trading session, reaching $72.85.

The company is trading down by 3.28% percent from yesterday's close. Marks and Spencer Group Plc (LON:MKS) has 0.00% since November 14, 2016 and is. It has outperformed by 7.46% the S&P500. The data from the past twelve months tells a similar story: insiders executed 21 buys and 46 sells, and ownership decreased by a net of 1.48 million shares.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned "Buy" rating by Jefferies on Tuesday, September 6. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.13 by $0.14. During the same quarter in the prior year, the company earned $2.75 earnings per share. sell-side analysts predict that Gilead Sciences will post 8.53 earnings per share for the current year. Its position was worth $814,453,000 an increase of 5.2% as of the end of the quarter.

Institutions own 75.10% of Gilead Sciences, Inc. American Beacon Advisors Inc. acquired a new stake in Gilead Sciences in the 1st quarter valued at $143,000. Gilead Sciences's dividend payout ratio (DPR) is 23.66%. Usca Ria LLC raised its position in Gilead Sciences by 203.3% in the first quarter. (NASDAQ:GILD) earned "Buy" rating by Mizuho on Tuesday, July 25. Its down 0.75, from 1.63 in 2017Q1. The stock was sold at an average price of $74.86, for a total value of $7,860,300.00.

Other hedge funds have also recently added to or reduced their stakes in the company. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. Forte Cap Limited Liability Co Adv, a New York-based fund reported 36,575 shares. Virginia Retirement Et Al stated it has 152,900 shares or 0.09% of all its holdings. Thematic Prtnrs Lc invested 2.38% in Gilead Sciences, Inc. Tctc Holding Lc invested 0.02% in Gilead Sciences, Inc. First Dallas Securities invested in 0.28% or 5,351 shares. With the existing current ratio, Gilead Sciences, Inc.is more than equipped to confront its liabilities with its assets. (NASDAQ:GILD). Ashfield Capital Prns Ltd Co has invested 0.03% of its portfolio in Gilead Sciences, Inc. Bp Public Ltd Company reported 151,000 shares. 343,686 are held by Rothschild Asset Mngmt. Gilead Sciences, Inc. has a quick ratio of 3.6 measuring its ability to meet its short term obligations with its most liquid assets.

Why a 12-Year-Old Is Suing Jeff Sessions Over Legal Marijuana
When she grows up she wants to be free to choose where she lives and what she does for a living. Alexis isn't the only one suing the government over access to medical marijuana .

TRADEMARK VIOLATION WARNING: "Essex Financial Services Inc". Oppenheimerfunds, Inc. expanded its position by buying 18,294 shares an increase of 0.2% in the quarter. Therefore 60% are positive. The original version of this report can be accessed at https://www.truebluetribune.com/2017/11/15/gilead-sciences-inc-gild-given-a-77-00-price-target-by-mizuho-analysts.html. Gilead Sciences has a consensus rating of "Buy" and a consensus target price of $84.87. The firm has "Equal-Weight" rating given on Friday, October 2 by Morgan Stanley. The firm has "Market Perform" rating given on Friday, December 4 by Wells Fargo. The rating was maintained by Oppenheimer with "Outperform" on Wednesday, July 29.

Analysts have given a mean recommendation of 1.80 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Stifel Nicolaus has "Buy" rating and $5800 target. The firm has "Buy" rating by TH Capital given on Monday, July 27.

Investors sentiment decreased to 0.88 in 2017 Q2. Ishares Inc was reduced too. 108 funds opened positions while 357 raised stakes.

Institutional investors and hedge funds have recently bought and sold shares of the company. Smith Salley Assocs accumulated 24,281 shares. 6,930 are owned by Williams Jones And Assoc Ltd Liability Corporation. Proshare Advisors Limited invested in 936,513 shares. Wealth Architects Limited Company stated it has 1,854 shares. The Premier Asset Managment Llc holds 11,450 shares with $810,000 value, down from 162,781 last quarter. Shareholders of record on Thursday, December 15th were given a $0.47 dividend. Fagan Associates stated it has 2.54% of its portfolio in Mastercard Inc (NYSE:MA). M Holding Inc has invested 0.22% in Abbott Laboratories (NYSE:ABT). 202,224 are held by Biondo Investment Limited Liability Com. Paradigm Cap Mgmt Incorporated invested 0.02% of its portfolio in Abbott Laboratories (NYSE:ABT). Denali Advsr Limited Liability Com holds 1.72% or 148,877 shares. The stock rose 1.35% or $0.74 reaching $55.46. MA's profit will be $1.19 billion for 33.56 P/E if the $1.12 EPS becomes a reality. Marshall Wace Llp sold 13,387 shares as Abbott Labs (ABT)'s stock declined 3.42%.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.